Bullet point summary
What is already known:
dFG-5 showed potent anti-iXase and antithrombotic activity without effects on f.XII and platelets
What this study adds:
Clinical significance:
The selective iXase inhibitor dHG-5 is a potential candidate for treating venous thrombosis